Urine Tests and Empagliflozin for Chronic Kidney Disease Patients
Studies urine markers and real-world empagliflozin use in people with chronic kidney disease.
Plain-language title generated from the registry record
Registry title: Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors
Key facts
- Where
- Salamanca, SpainSee the site
Where in Spain
- Hospital Universitario De SalamancaSalamanca, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Instituto de Investigación Biomédica de Salamanca
- Trial code
- NCT07348484
- Record updated
- 5 November 2026
- Original description
This prospective observational study aims to assess the association between real-world use of sodium-glucose co-transporter 2 inhibitors (SGLT2i; e.g., empagliflozin, dapagliflozin) and renal function decline in adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification). The study will also validate a urinary biomarker panel for early diagnosis and monitoring of CKD progression.Read full original descriptionShow less
Diagnostic and Monitoring System for Chronic Kidney Disease Based on Urinary Biomarkers and Preventive Treatment With the SGLT2 Inhibitor Empagliflozin
This prospective observational study aims to assess the association between real-world use of sodium-glucose co-transporter 2 inhibitors (SGLT2i; e.g., empagliflozin, dapagliflozin) and renal function decline in adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification). The study will also validate a urinary biomarker panel for early diagnosis and monitoring of CKD progression.
No investigational product is assigned, and medical practice or prescription patterns are not altered.
Inclusion: ≥18 years old; Diagnosed with chronic kidney disease (KDIGO stages 2-4); Life expectancy ≥12 months; Available clinical and laboratory data in the electronic medical record.
Exclusion: Current or recent renal replacement therapy or kidney transplantation; End-stage renal disease; Allergy or intolerance to SGLT2i (for exposed cohort); Participation in interventional trials that may affect outcomes.